Roche adds $25M to Halozyme pact for fresh targets; FDA OKs cardio indication for J&J's Invokana
→ Building on a 12-year-old partnership, Roche has doled out $25 million to develop up to three more …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
